Dianthus Therapeutics (DNTH) AI Stock Analysis

• Market Cap: $1.32B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -42.64%
• EPS Growth: -39.78%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.97
• Shares Outstanding: 39,816,223
• 10 Day Avg. Volume: 588,847
• 30 Day Avg. Volume: 1,003,841
• PEG Ratio: 0.12
• Price to Book (P/B): 2.06
• Price to Sales (P/S): 116.48
• P/FCF Ratio: -9.28
• Enterprise Value/Market Cap: 0.31
• Enterprise Value/Revenue: 133.63
• Enterprise Value/Gross Profit: 133.63
• Enterprise Value/Ebitda: -3.01
• 1Y Price Target: $69.15
• Price Target Upside: 66.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $37.00 ▼(-10.74% Downside)

Dianthus Therapeutics' overall stock score is primarily influenced by its financial performance challenges, including declining revenues and negative profitability. Technical analysis shows positive momentum, which provides some optimism. However, the negative valuation metrics due to unprofitability weigh down the score.

Positive Factors

Gross Profit Margin

A high gross profit margin indicates effective cost management and pricing power, which can support long-term profitability if revenue stabilizes.

Low Leverage

Minimal leverage provides financial flexibility and reduces risk, allowing the company to invest in growth opportunities without significant debt burden.

Free Cash Flow Growth

Growth in free cash flow suggests improving cash generation, which can fund operations and future development without relying on external financing.

Negative Factors

Declining Revenue

A significant decline in revenue challenges the company's ability to sustain operations and invest in R&D, impacting long-term growth prospects.

Negative Profitability

Persistent losses and negative margins indicate operational inefficiencies, which may hinder the company's ability to achieve sustainable profitability.

Negative Operating Cash Flow

Negative operating cash flow suggests the company struggles to generate cash from core operations, potentially limiting its ability to fund growth initiatives.

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

Dianthus Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. This includes income from licensing agreements with larger pharmaceutical companies, where Dianthus may receive upfront payments, milestone payments based on developmental progress, and royalties on sales of approved products. Additionally, the company may secure funding through grants and partnerships with research institutions or other biotech firms. The successful advancement of its clinical pipeline, particularly in attracting investments for further development and eventual market launch of therapies, is crucial for its revenue generation.

Dianthus Therapeutics Financial Statement Overview

Summary

Dianthus Therapeutics faces significant financial challenges with declining revenues and persistent losses. While the company maintains a strong gross profit margin and low leverage, its negative profitability metrics and cash flow issues highlight operational inefficiencies.

Income Statement

Dianthus Therapeutics shows a declining revenue trend with a significant drop of 36.59% in TTM. The company has a high gross profit margin of 97.96% in TTM, indicating efficient cost management. However, the net profit margin is deeply negative at -23.64%, reflecting substantial losses. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet is relatively stable with a low debt-to-equity ratio of 0.0044 in TTM, suggesting minimal leverage. However, the return on equity is negative at -34.72%, indicating inefficiencies in generating returns on shareholder investments. The equity ratio is healthy, showing a strong equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a positive free cash flow growth rate of 9.24% in TTM, but operating cash flow remains negative, indicating cash burn. The operating cash flow to net income ratio is -4.99, suggesting challenges in converting earnings into cash. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is in line with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.08M	6.24M	2.83M	6.42M	1.48M	0.00
Gross Profit	3.08M	6.24M	2.83M	6.42M	1.48M	-1.98M
EBITDA	-136.45M	-101.45M	-47.82M	-29.56M	-13.09M	-72.96M
Net Income	-126.34M	-84.97M	-43.55M	-28.48M	-13.11M	-74.94M
Balance Sheet
Total Assets	577.45M	374.01M	179.41M	83.11M	189.93M	161.62M
Cash, Cash Equivalents and Short-Term Investments	402.61M	275.24M	173.72M	75.49M	176.93M	148.84M
Total Debt	1.28M	1.49M	585.00K	788.00K	0.00	0.00
Total Liabilities	30.99M	21.53M	10.54M	9.45M	17.26M	17.71M
Stockholders Equity	546.45M	352.48M	168.87M	73.66M	172.67M	143.91M
Cash Flow
Free Cash Flow	-109.63M	-78.28M	-36.97M	-29.21M	-60.80M	-64.42M
Operating Cash Flow	-109.52M	-78.18M	-36.86M	-29.07M	-59.53M	-64.02M
Investing Cash Flow	-183.15M	-286.81M	20.25M	-59.82M	43.43M	-10.63M
Financing Cash Flow	314.92M	255.62M	133.57M	96.68M	89.60M	67.74M

Dianthus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 41.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 41.45 is above the 20-day moving average (MA) of 36.37, above the 50-day MA of 36.35, and above the 200-day MA of 24.65, indicating a bullish trend. The MACD of 1.65 indicates Negative momentum. The RSI at 62.64 is Neutral, neither overbought nor oversold. The STOCH value of 68.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.

Dianthus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DNTH	55 Neutral	$1.32B	-10.20	-28.57%	―	-42.64%	-39.78%
ARDX	55 Neutral	$1.35B	―	-36.18%	―	58.12%	24.08%
JANX	55 Neutral	$1.73B	―	-12.48%	―	-23.37%	-42.45%
AMLX	52 Neutral	$1.57B	―	-56.52%	―	-100.34%	52.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EWTX	40 Underperform	$2.37B	―	-30.02%	―	―	-5.73%
BHVN	40 Underperform	$1.00B	―	-522.08%	―	―	18.76%

Dianthus Therapeutics Corporate Events

Dianthus Therapeutics Reports Q3 2025 Financial Results

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases, headquartered in New York, New York. In its latest earnings report for the quarter ending September 30, 2025, Dianthus Therapeutics highlighted significant financial activities, including a substantial increase in cash and investments, driven by a successful public offering. The company reported a net loss of $36.8 million for the quarter, reflecting its ongoing investment in research and development. Key financial metrics include total revenues of $396,000 and operating expenses of $40.7 million, primarily attributed to research and development costs. Despite the losses, the company successfully raised $288.4 million through a public offering, bolstering its financial position with $577.4 million in total assets. Looking ahead, Dianthus Therapeutics remains focused on advancing its clinical and preclinical development activities, with management expressing confidence in its ability to fund operations for at least the next twelve months.

Dianthus Therapeutics Reports Positive Phase 2 Results

On November 3, 2025, Dianthus Therapeutics updated its corporate presentation, highlighting its progress in developing claseprubart and DNTH212 for autoimmune diseases. The company reported positive Phase 2 results for claseprubart in generalized myasthenia gravis, and plans to initiate Phase 3 trials in 2026, positioning itself as a leader in the neuromuscular market. This advancement could significantly impact the treatment landscape for autoimmune diseases, offering more convenient and potentially superior therapeutic options.

The most recent analyst rating on (DNTH) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Therapeutics Advances CIDP Treatment with DNTH103 Study

Study Overview: Dianthus Therapeutics, Inc. is conducting a Phase 3 study titled ‘CAPTIVATE’ to evaluate the efficacy and safety of DNTH103 in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The study aims to demonstrate the effectiveness of DNTH103 compared to a placebo, which is significant for advancing treatment options for CIDP patients.

Dianthus Therapeutics Advances Phase 2 Study of DNTH103 for Neuropathy

Study Overview: Dianthus Therapeutics, Inc. is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM). The study aims to assess the safety and effectiveness of DNTH103 in treating multifocal motor neuropathy (MMN), a rare neurological disorder. This research is significant as it could lead to new treatment options for MMN patients.

Dianthus Therapeutics Signs License Agreement with Nanjing Leads

On October 16, 2025, Dianthus Therapeutics entered into a License and Collaboration Agreement with Nanjing Leads Biolabs, granting Dianthus an exclusive license outside Greater China to develop and commercialize DNTH212, a bifunctional fusion protein targeting immune system pathways. This agreement involves significant financial commitments, including up to $38 million in upfront and milestone payments, and potential royalties for Leads. The collaboration aims to enhance Dianthus’ position in the autoimmune disease therapeutics market, with DNTH212 showing potential for superior clinical efficacy compared to existing treatments.

The most recent analyst rating on (DNTH) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Therapeutics Raises $270M Through Stock Offering

On September 9, 2025, Dianthus Therapeutics, Inc. entered into an underwriting agreement to issue and sell 6,487,879 shares of its common stock and pre-funded warrants to purchase 1,112,121 shares, raising approximately $270 million. This financial move, expected to close on September 11, 2025, is aimed at strengthening the company’s capital position and enhancing its market presence, with implications for its stakeholders and industry positioning.

The most recent analyst rating on (DNTH) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.

Dianthus Therapeutics Reports Positive Phase 2 Trial Results

On September 8, 2025, Dianthus Therapeutics announced positive top-line data from its Phase 2 MaGic trial for claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG). The trial demonstrated statistically significant and clinically meaningful improvements in key efficacy endpoints, with a favorable safety profile. These results support the potential best-in-class profile of claseprubart and bolster confidence in future clinical programs.

The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.